

7. AML Academy 2024

Study Alliance Leukemia – AML Cooperative Group – CELL



SAL
Studienallianz
Leukämie

AMLCG
AML
Cooperative Group

14th/15th November 2024

PRELIMINARY AGENDA

Thursday, 14th November 2024

AML Academy I

13:00–13:10	Welcome	
13:10–13:30	Infections in AML patients during remission induction	Sabine Ehrlich
13:30–13:50	Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in AML	Julian Ronnacker
13:50–14:10	Histone demethylation tones down leukemia through innate immunity	Mari F. Arteaga
14:10–14:25	German Cancer Registries and the SAL-AML Registry – Any correlations?	David Baden
14:25–14:45	AI for diagnostics and risk stratification in AML	Moritz Middeke
15:15–15:35	Long-term survival after AML treatment	Klaus Metzeler
15:35–16:00	Treatment of relapsed/refractory AML: non-intensive approaches and other options	Tim Sauer
16:00–16:30	Transplant in AML: Standards and open questions	Gesine Bug

AML Academy II

17:00–17:30	Clonal Hematopoiesis: What's new and are there real clinical implications?	Gerwin Huls
17:30–18:00	AML in first CR: What to do next?	Richard Dillon
18:00–18:45	How I treat high-risk AML now and in 5 years	David Sallman
18:45–18:55	Closing remarks	
From 19:30	Networking dinner	

Friday, 15th November 2024

SAL-AMLCG Steering Committee Meeting

08:00–10:00 Steering Committee Meeting

Joint Study Group Meeting of SAL, AMLCG

10:30–13:00 Updates on current, past and future projects and trials

Lunch Break

14:00–16:00 Updates on current, past and future projects and trials

Organizer

GWT Gesellschaft für
Wissens- und
Technologietransfer

GWT-TUD GmbH
Freibergerstr. 33
01067 Dresden

Juliana Binder
Mobil: 0151 2333 7972
juliana.binder@g-wt.de

Location

Scandic Frankfurt Museumsufer
Wilhelm-Leuschner-Straße 44
60329 Frankfurt am Main

Und online via Zoom

Registration
www.aml-academy.de

Sponsors



Main Sponsor
abbvie

Abbvie Deutschland GmbH & Co. KG [20.000,00 €], Astellas Pharma GmbH [5.000,00 €], BeiGene Ltd. [5.000,00 €], Bristol-Myers Squibb GmbH & Co. KGaA [5.000,00 €], Novovii Biotech GmbH [5.000,00 €], Pfizer [10.000,00 €], Stemline Therapeutics Switzerland GmbH [5.000,00 €], Otsuka Pharma GmbH [10.000,00 €], Daiichi Sankyo Deutschland GmbH [10.000,00 €]